Cover Story
FreeGuest Editorial
The ever-rising cost of oncology drugs is doing damage to cancer care on many levels.
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
Trending Stories
- Trump 2016: A look back at the 45th president’s impact on oncology
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.” - A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment - At an uncertain time for cancer research and public health, Wayne Frederick steps in as interim CEO at ACS
- Long-term risks from prostate cancer treatment detailed in new report
- FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients